Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Frontiers in Cardiovascular Medicine

Remnant lipoproteins and remnant cholesterol in residual atherosclerotic cardiovascular risk

4 affiliations
  1. 1Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, First Affiliated Hospital of Gannan Medical University, Gannan Medical University
  2. 2Heart Medical Center, The First Affiliated Hospital of Gannan Medical University
  3. 3First Clinical Medical College, Gannan Medical University
  4. 4The First Affiliated Hospital of Gannan Medical University

Abstract

Despite intensive lowering of low-density lipoprotein cholesterol (LDL-C), many patients continue to experience atherosclerotic cardiovascular disease (ASCVD) events, with cholesterol-enriched remnant lipoproteins contributing to this residual risk. This review examines the evidence linking remnant lipoproteins to residual ASCVD risk and evaluates which treatment-induced changes in remnant exposure are likely to reduce it. Lipoprotein lipase (LPL), transported to the capillary lumen by GPIHBP1, converts triglyceride-rich lipoproteins into smaller remnants, the concentration of which is then determined by further remodeling and hepatic uptake. Once retained in the arterial wall, these remnants deliver cholesterol to macrophages and promote inflammation. In cohort studies, remnant cholesterol (RC) predicts cardiovascular events even among patients receiving lipid-lowering therapy, while Mendelian randomization and coding-variant analyses implicate LPL and its regulators in coronary artery disease. Trials evaluating triglyceride-lowering therapies, however, have yielded inconsistent results. In PROMINENT, pemafibrate lowered RC but elevated apolipoprotein B (apoB) and failed to reduce events. Agents targeting apolipoprotein C-III or angiopoietin-like protein 3 substantially lower triglycerides; their effects on RC, LDL-C, and apoB differ by agent and population; in the ESSENCE imaging study, olezarsen reduced both RC and apoB without significantly altering non-calcified plaque volume at 1 year. Building upon recent syntheses, we propose that these findings are best interpreted by separating four related dimensions of exposure: the cholesterol carried per remnant particle, the number of remnant particles, total apoB-containing particle exposure, and the rate of particle clearance. We apply this remnant-cholesterol-load framework to classify trial responses and to identify the measurements that future outcome trials should include. The framework is interpretive, and its dimensions are mathematically and kinetically related rather than independent; it has not been tested prospectively. At present, RC serves as a useful complement in assessing residual dyslipidemia; whether its reduction decreases events will be established only by outcome trials incorporating serial lipid and particle measurements.

Related

  1. Remnant cholesterol and cardiovascular risk in maintenance haemodialysis
    Clinical kidney journalPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Association of remnant cholesterol inflammatory index and hypertension with incident cardiovascular disease
    Yaona Li, Chuhui Yue, Sujun Yuan +6
    BMC Public HealthPeer-reviewedCC BY 4.0Epidemiology & public healthCrossref
  3. Residual atherosclerotic cardiovascular disease risk in statin-treated patients: mechanisms, therapeutic strategies, and future directions—a scoping review
    Muhammad Abdul Rehman, Malik Olatunde Oduoye, Davidson John Ozoemena +3
    Frontiers in cardiovascular medicinePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  4. Residual Risk From Remnant Cholesterol and Inflammation Despite Lipid‐Lowering Therapy and Association With Incident Peripheral Artery Disease in Type 2 Diabetes
    Ruoxi Liao, Zhiwen Xiao, Chixiong Huang +7
    Journal of the American Heart AssociationPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaCrossrefDOAJ
  5. Remnant cholesterol, C-reactive protein, cholesterol-lowering medication, and cardiovascular outcome: novel findings from UK Biobank.
    Jing Chen, Xuan Song, Jian-Jun Li +1
    Frontiers in nutritionPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
BibTeX
@article{huang2026remnant,
  title = {{Remnant lipoproteins and remnant cholesterol in residual atherosclerotic cardiovascular risk}},
  author = {Yuting Huang and Luyao Lin and Feng Liu and Xiaoping Wang},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  month = nov,
  doi = {10.3389/fcvm.2026.1967973},
  url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1967973/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Remnant lipoproteins and remnant cholesterol in residual atherosclerotic cardiovascular risk
AU  - Yuting Huang
AU  - Luyao Lin
AU  - Feng Liu
AU  - Xiaoping Wang
PY  - 2026
DA  - 2026/11/16
JO  - Frontiers in Cardiovascular Medicine
DO  - 10.3389/fcvm.2026.1967973
UR  - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1967973/full
AB  - Despite intensive lowering of low-density lipoprotein cholesterol (LDL-C), many patients continue to experience atherosclerotic cardiovascular disease (ASCVD) events, with cholesterol-enriched remnant lipoproteins contributing to this residual risk. This review examines the evidence linking remnant lipoproteins to residual ASCVD risk and evaluates which treatment-induced changes in remnant exposure are likely to reduce it. Lipoprotein lipase (LPL), transported to the capillary lumen by GPIHBP1, converts triglyceride-rich lipoproteins into smaller remnants, the concentration of which is then determined by further remodeling and hepatic uptake. Once retained in the arterial wall, these remnants deliver cholesterol to macrophages and promote inflammation. In cohort studies, remnant cholesterol (RC) predicts cardiovascular events even among patients receiving lipid-lowering therapy, while Mendelian randomization and coding-variant analyses implicate LPL and its regulators in coronary artery disease. Trials evaluating triglyceride-lowering therapies, however, have yielded inconsistent results. In PROMINENT, pemafibrate lowered RC but elevated apolipoprotein B (apoB) and failed to reduce events. Agents targeting apolipoprotein C-III or angiopoietin-like protein 3 substantially lower triglycerides; their effects on RC, LDL-C, and apoB differ by agent and population; in the ESSENCE imaging study, olezarsen reduced both RC and apoB without significantly altering non-calcified plaque volume at 1 year. Building upon recent syntheses, we propose that these findings are best interpreted by separating four related dimensions of exposure: the cholesterol carried per remnant particle, the number of remnant particles, total apoB-containing particle exposure, and the rate of particle clearance. We apply this remnant-cholesterol-load framework to classify trial responses and to identify the measurements that future outcome trials should include. The framework is interpretive, and its dimensions are mathematically and kinetically related rather than independent; it has not been tested prospectively. At present, RC serves as a useful complement in assessing residual dyslipidemia; whether its reduction decreases events will be established only by outcome trials incorporating serial lipid and particle measurements.
SN  - 2297-055X
ER  -